Figshare
open access
CC BY 4.0
Supplemental material for: Real-world effectiveness and safety of budesonide MMX in Japanese patients with ulcerative colitis: A multicenter retrospective study
Introduction: Budesonide Multi-Matrix System (BUD-MMX) was approved in Japan in 2023 for active ulcerative colitis (UC); however, real-world data in Asian population are limited. We evaluated the real-world effectiveness and safety of BUD-MMX in Japanese patients with UC. <p dir="ltr
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Budesonide Multimatrix(MMX) Versus Prednisolone in Management of Mild to Moderate Ulcerative Colitis#1228986
- Combination of Diet and Oral Budesonide for Ulcerative Colitis#908040
- Budesonide 9 mg Capsules in Active UC#1044391
- (CB-01-02/04) Extension Study of Budesonide Multi-Matrix System (MMX) 6 mg in Maintenance Of Remission In Patients With Ulcerative Colitis.#1124689
- (CB-01-02/06) Oral Budesonide-Multi-Matrix System (MMX) 9mg Extended Release Tablets#1074694
Record · ID 1263687
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive